Dr. Naughton recognizes the difference between risk of recurrence and likelihood of benefit from extended endocrine therapy, noting the two do not always correlate, as they can be based on separate biological mechanisms. A patient at high risk of recurrence does not inherently imply that patient will respond to a particular therapy.